Skip to main content

65 - References

References

Addictions and substance misuse CHAPTER 4 References

  1. Couchman L, et al. Amisulpride and sulpiride interfere in the CEDIA DAU buprenorphine test. Ann Clin Psychiatry 2008; 45 Suppl 1.
  2. Merative US L.P. Micromedex. 2024; https://www.micromedexsolutions.com/home/dispatch/.
  3. Substance Abuse and Mental Health Services Administration (US). Substance Abuse: Clinical Issues in Intensive Outpatient Treatment. Treatment Improvement Protocol (TIP) Series, No. 47. 2006.
  4. Vandevenne M, et al. Detection time of drugs of abuse in urine. Acta Clin Belg 2000; 55:323–333.
  5. Brahm NC, et  al. Commonly prescribed medications and potential false-­positive urine drug screens. Am J Health Syst Pharm 2010; 67:1344–1350.
  6. Saitman A, et al. False-­positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol 2014; 38:387–396.
  7. Liu CH, et al. False positive ketamine urine immunoassay screen result induced by quetiapine: a case report. J Formos Med Assoc 2017; 116:720–722.
  8. Shoptaw SJ, et al. Treatment for amphetamine psychosis. Cochrane Database Syst Rev 2009; 1:CD003026.
  9. Farley TM, et al. False-­positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use. BMJ Case Rep 2017; 2017:bcr-­2017-­222106.
  10. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178:116–122.
  11. Hall W, et al. Long-­term cannabis use and mental health. Br J Psychiatry 1997; 171:107–108.
  12. Murray RM, et al. Traditional marijuana, high-­potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry 2016; 15:195–204.
  13. Marconi A, et  al. Meta-­analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016; 42:1262–1269.
  14. Arseneault L, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184:110–117.
  15. Budney AJ, et al. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161:1967–1977.
  16. Bonnet U, et al. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil 2017; 8:9–37.
  17. Schröck A, et al. Pharmacokinetics of GHB and detection window in serum and urine after single uptake of a low dose of GBL – an ­experiment with two volunteers. Drug Test Anal 2014; 6:363–366.
  18. Busardò FP, et al. Ultra-­high performance liquid chromatography tandem mass spectrometry (UHPLC-­MS/MS) for determination of GHB, precursors and metabolites in different specimens: application to clinical and forensic cases. J Pharm Biomed Anal 2017; 137:123–131.
  19. Bowden-­Jones O, et al. on behalf of the NEPTUNE Expert Group. Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE); 2015.
  20. Chen WY, et al. Gender differences in subjective discontinuation symptoms associated with ketamine use. Subst Abuse Treat Prev Policy 2014; 9:39.
  21. Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction 2006; 101:1212–1213.
  22. Adamowicz P, et  al. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and ­detection window considerations. J Anal Toxicol 2005; 29:376–382.
  23. Passie T, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 2008; 14:295–314.
  24. Gov.UK Advisory Council on Misuse of Drugs. Research and analysis: ACMD advice on 2-­benzyl benzimidazole and piperidine benzimidazolone opioids (accessible version). 2024; https://www.gov.uk/government/publications/acmd-­advice-­on-­2-­benzyl-­benzimidazole-­and-­piperidine-­ benzimidazolone-­opioids/acmd-­advice-­on-­2-­benzyl-­benzimidazole-­and-­piperidine-­benzimidazolone-­opioids-­accessible-­version.
  25. Advisory Council on the Misuse of Drugs. ACMD report – misuse of fentanyl and fentanyl analogues. 2020; https://assets.publishing.service. gov.uk/media/5e0f5952e5274a0f9bccd774/ACMD_Report_-­_Misuse_of_fentanyl_and_fentanyl_analogues.pdf.
  26. Tebo C, et al. Suspected synthetic cannabinoid receptor agonist intoxication: does analysis of samples reflect the presence of suspected agents? Am J Emerg Med 2019; 37:1846–1849.
  27. Malaca S, et al. Pharmacology and toxicology of xylazine: quid novum? Eur Rev Med Pharmacol Sci 2023; 27:7337–7345.
  28. Truver MT, et al. A quantitative LC-­MS/MS analysis of xylazine, p-­fluorofentanyl, fentanyl and fentanyl-­related compounds in postmortem blood. J Chromatogr B Analyt Technol Biomed Life Sci 2024; 1237:124059.
  29. Moeller KE, et al. Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens. Mayo Clin Proc 2017; 92:774–796.

No comments to display

Back to top